Abstract: Provided is a processed food containing uric acid, wherein a content (X) of uric acid is 0.001 ?g/g or more.

Abstract: An object of the present invention is to provide an alcoholic beverage having a reduced sensation of irritation of alcohol. The weight ratio (A/B) of (A) cis-3-hexen-1-ol to (B) ?-terpineol in the beverage is adjusted to 35 or more and 30,000 or less, and the content of cis-3-hexen-1-ol is adjusted to 90.000 ppb or less.

Abstract: The present invention aims to provide a composition for increasing leukocytes and/or basophils, a composition for inhibiting epidermal growth factor receptor (EGER) tyrosine kinase, a composition for activating innate immunity, a method of increasing leukocytes and/or basophils, a method of inhibiting epidermal growth factor receptor (EGFR) tyrosine kinase, and a method of activating innate immunity. The present invention relates to a composition for increasing leukocytes and/or basophils, which contains L-ergothioneine or a salt thereof as an active ingredient.

Abstract: The present invention provides a stevia plant having a genotype C/C at a position corresponding to position 37 of SEQ ID NO: 1. The present invention also provides a method of producing the stevia plant, and an extract obtained from the plant.

Abstract: The present invention provides a beverage comprising an infusion of a citrus fruit. Also provided are methods for the production of a citrus fruit infusion and ingredients, concentrates and beverages comprising said infusion.

Abstract: The present invention aims to provide a composition for promoting lipolysis and a method of promoting lipolysis. The present invention relates to a composition for promoting lipolysis, the composition containing L-ergothioneine or a salt thereof as an active ingredient.

Abstract: The present invention aims to provide a composition for increasing at least one of red blood cell count or hemoglobin level, a composition for preventing or reducing anemia, a composition for improving endurance, an antifatigue composition, a method of increasing at least one of red blood cell count or hemoglobin level, a method of preventing or reducing anemia, a method of improving endurance, and a method of reducing, alleviating, or preventing fatigue or recovering from fatigue. The present invention relates to a composition for increasing at least one of red blood cell count or hemoglobin level, containing L-ergothioneine or a salt thereof as an active ingredient.

Abstract: The present invention aims to provide an anxiolytic composition for humans and a method of preventing or reducing an anxiety symptom. The present invention relates to an anxiolytic composition for humans, containing L-ergothioneine or a salt thereof as an active ingredient.

Abstract: The present invention relates to a food or beverage having enhanced sweetness exhibited by a sugar and a sweetener, a sweetening composition for producing the food or beverage, and a method for producing the food or beverage.

Abstract: The present invention aims to provide a composition for reducing renal function decline or ameliorating renal function and a method of reducing renal function decline or ameliorating renal function. The present invention relates to a composition for reducing renal function decline or ameliorating renal function, the composition containing L-ergothioneine or a salt thereof as an active ingredient.

Abstract: Provided is an oral composition comprising (a) a high-intensity sweetener in an amount corresponding to a sweetness intensity X1, (b) an intrinsic phospholipid, and (c) a foreign phospholipid in an amount less than a taste recognition threshold, wherein the oral composition has a sweetness of a sweetness intensity X2 exhibited by the components (a) and (b), and a sweetness of a sweetness intensity X3 exhibited by the components (a) to (c), respectively, and 0.1<X2<X3 is satisfied.

Abstract: Provided is an oral composition comprising (a) a high-intensity sweetener in an amount corresponding to a sweetness intensity X1, and (b) a phospholipid in an amount less than a taste recognition threshold, wherein the oral composition has a sweetness of a sweetness intensity X2 exhibited by the components (a) to (b), respectively, and 0.1<X1<X2 is satisfied.

Abstract: An oxygen-shielding container lid according to the present invention comprises a high density polyethylene cap shell 1 having a skirt section 7 and a top plate section 5 provided with an inner ring 9 for intimate contact with an inner surface of a container mouth; and an in-shell molded body 3 provided in a portion of an inner surface of the top plate section which is surrounded with the inner ring 9. The in-shell molded body 3 is composed of a primary molded body 3a which has been formed by in-shell molding on the inner surface of the top plate section and which has an oxygen shielding function; and a secondary molded body 3b which has been formed on the primary molded body 3a by in-shell molding so as to cover the primary molded body 3a and to be fused and fixed to the inner surface of the top plate section at the peripheral edge of the primary molded body. A resin composition used for formation of the secondary molded body 3b contains linear low density polyethylene, and has a melt flow rate at 190° C.

Abstract: The present invention aims to provide a composition for improving a blood cholesterol level and a method of improving a blood cholesterol level. The present invention relates to a composition for improving a human blood cholesterol level, which contains L-ergothioneine or a salt thereof as an active ingredient.

Abstract: The present invention aims to provide a corosolic acid-containing beverage with an increased solubility of corosolic acid in water and a method of producing the same. The present invention relates to a corosolic acid-containing beverage that is a beverage containing corosolic acid, the beverage containing: at least one type of epicatechin compound selected from the group consisting of epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate, wherein a corosolic acid content is 1 ppm or higher and corosolic acid is at least partially dissolved in the beverage.

Abstract: The present invention aims to provide a composition for promoting immune cell metabolism, a composition for activating immunity, a method of promoting immune cell metabolism, and a method of activating immunity. The present invention relates to a composition for promoting immune cell metabolism, which contains L-ergothioneine or a salt thereof as an active ingredient.

Abstract: Conventionally, it has not been possible to easily know the user's blood sugar constitution type. It is possible to easily know the user's blood sugar constitution type using a blood sugar constitution determination device including: a storage unit that stores one or more pieces of question information that are used to judge a blood sugar constitution type and include a question regarding lifestyle; an output unit that outputs the one or more pieces of question information; an acceptance unit that accepts, from a user, answer information corresponding to the one or more pieces of question information; a processing unit that determines a blood sugar constitution type of the user, using the one or more pieces of answer information accepted by the acceptance unit; and an information output unit that outputs output information regarding the blood sugar constitution type.

Abstract: There is a demand for the development of a novel beverage containing an alternative sweetener to sugar. The present invention provides a beverage containing 0.1-25 w/v % of D-arabinose.

Abstract: The purpose of the present invention is to provide a crystal of rebaudioside D that exhibits high solubility in water. In one embodiment, the present invention provides a rebaudioside D crystal having a crystalline form ? that shows peaks in X-ray diffraction (CuK?: ?=1.5405 ?) at two or more positions selected from the group consisting of 2?=6.7±0.2 deg, 10.8±0.2 deg, 12.9±0.15 deg, and 22.2±0.2 deg.

Abstract: The present invention aims to provide a novel method that can quantify diaminopimelic acid-containing bacteria in a test sample. The present invention relates to a method of quantifying diaminopimelic acid-containing bacteria in a test sample, including a step of quantifying the diaminopimelic acid-containing bacteria, using, as an index, the amount of diaminopimelic acid derived from the diaminopimelic acid-containing bacteria in the test sample.